Aaron Venables joins as InsituGen CEO

InsituGen are excited to announce that Aaron Venables has taken on the role of CEO, effective 20th June 2023.

Chairman of the board, Dr. Gary Pace, has commented “Aaron’s 24 years of experience in the life sciences and biotechnology industries, both at start-ups and multi-billion dollar corporate organisations, will add significant commercial expertise to InsituGen’s team during a new phase of commercialisation of our technology.”

Dr. Pace added “Based in the United Kingdom, Aaron will form an effective team in Europe with InsituGen Founder and Chief Scientific Officer, Professor Alison Heather (Cambridge, UK), and InsituGen board member and veterinarian Dr Oliver Gehrig (Germany).”

Aaron has global, cross-functional experience leading teams in the UK, Switzerland, Germany, France, USA, Australia, China, and Korea. He has served as Chief Commercial Officer for Sampled (a New Jersey based CRO and Biorepository serving large Pharmaceutical and Government contracts), as Chief Commercial Officer for Fluidic Analytics (a University of Cambridge start-up specializing in protein:protein interactions), as General Manager and Executive Director of Weatherbys Scientific and Weatherbys Scientific Australia (an agrigenomics service laboratory in the horseracing and livestock industries, providing testing for better animal health and productivity through genetic data-driven decisions), and at Thermo Fisher Scientific as Chief of Staff to the President during which time he was part of a small team that built the UK’s first personalised medicine company – the Stratified Medicine Scotland Innovation Centre.

“I am delighted to have been appointed to lead InsituGen as its Chief Executive. It is a business with amazing growth potential based on the proprietary platform technology that can be applied to a multitude of applications from the current anti-doping in sports animals to wellness in companion animals, then food and water testing” commented Aaron, who then added “InsituGen has a talented and experienced board and team, and I am very much looking forward to working with all of them to achieve this potential.”